JAGUAR ANIMAL HEALTH,INC. (NASDAQ:JAGX) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders.

Jaguar Animal Health,Inc. (the Company) held its 2017 Annual
Meeting of Stockholders of the Company on May8, 2017. Three
proposals were submitted to and approved by the stockholders of
the Company. The proposals are described in detail in the
Companys Proxy Statement. The final results for the votes
regarding each proposal are set forth below.

1. Stockholders elected two ClassII directors to the Companys
Board of Directors to hold office for a three-year term until the
annual meeting of stockholders in 2020 and until their successors
are elected and qualified. The votes regarding this proposal were
as follows:

Jiahao Qiu and John Micek III

2. Stockholders ratified the selection of BDO USA, LLP as
independent registered public accounting firm for the fiscal year
ending December31, 2018. The votes regarding this proposal were
as follows:

3. The proposal to approve, to Nasdaq Listing Rule5635(d), the
issuance of additional shares of common stock to Aspire Capital
Fund LLC to the common stock purchase agreement dated June8, 2016
was approved by the stockholders by the following vote:

About JAGUAR ANIMAL HEALTH, INC. (NASDAQ:JAGX)

Jaguar Animal Health, Inc. is an animal health company. It is focused on developing and commercializing gastrointestinal products for companion and production animals, foals, and horses. Canalevia is its prescription drug product candidate, intended for treatment of various forms of diarrhea in dogs. Canalevia is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient (API) isolated and purified from the Croton lechleri tree. It is developing a pipeline of prescription drug product candidates and non-prescription (non-drug) products to address needs in animal health. As of December 31, 2016, its pipeline includes prescription drug product candidates for nine indications across multiple species, and non-prescription products targeting seven species. Its product candidates include Canalevia, Species-specific formulations of crofelemer, Equilevia, Virend (topical), Species-specific formulations of NP-500, Neonorm Calf and Species-specific formulations of Neonorm.

JAGUAR ANIMAL HEALTH, INC. (NASDAQ:JAGX) Recent Trading Information

JAGUAR ANIMAL HEALTH, INC. (NASDAQ:JAGX) closed its last trading session down -0.011 at 0.800 with 46,625 shares trading hands.